

Clinical Policy Title:	caplacizumab-yhdp
Policy Number:	RxA.51
Drug(s) Applied:	Cablivi®
Original Policy Date:	02/07/2020
Last Review Date:	03/09/2021
Line of Business Policy Applies to:	All lines of business

Background

Caplacizumab-yhdp (Cablivi®) is a von Willebrand factor (vWF)-directed antibody fragment. Cablivi® is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Dosing Information

Drug Name	Indication	Dosing Regimen	Maximum Dose
caplacizumab-yhdp (Cablivi®)	aTTP	<p><u>First day of treatment:</u> 11 mg bolus intravenous injection at least 15 minutes prior to plasma exchange followed by an 11 mg subcutaneous injection after completion of plasma exchange on day 1.</p> <p><u>Subsequent days of treatment during daily plasma exchange:</u> 11 mg subcutaneous injection once daily following plasma exchange.</p> <p><u>Treatment after plasma exchange period:</u> 11 mg subcutaneous injection once daily continuing for 30 days following the last daily plasma exchange. If after initial treatment course, sign(s) of persistent underlying disease such as suppressed ADAMTS13 activity levels remain present, treatment may be extended for a maximum of 28 days.</p>	<p>Loading: 22 mg/day</p> <p>Maintenance: 11 mg/day</p>

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

Dosage Forms

- Single-dose vials for injection: 11 mg

Clinical Policy

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

I. Initial Approval Criteria

A. Acquired Thrombotic Thrombocytopenic Purpura (must meet all):

1. Diagnosis of aTTP confirmed with a PLASMIC score of 6 to 7 (see Appendix D);
2. Prescribed by or in consultation with a hematologist;
3. Age \geq 18 years;
4. Prescribed in combination with plasma exchange therapy;
5. Prescribed in combination with immunosuppressive therapy (i.e., glucocorticoids, rituximab);
6. Dose does not exceed (a and b) (see Section V):
 - a. Loading dose on Day 1: 11 mg pre-plasma exchange and 11 mg post-plasma exchange (22 mg total);
 - b. Maintenance: 11 mg per day.

Approval Duration

Commercial: 30 days

Medicaid: 30 days

II. Continued Therapy Approval

A. Acquired Thrombotic Thrombocytopenic Purpura (must meet all):

1. Member is currently receiving medication that has been authorized by RxAdvance or member has previously met initial approval criteria listed in this policy;
2. Member meets one of the following (a or b):
 - a. If request is for a new treatment cycle, member has experienced no more than two recurrences (see Appendix D) while taking Cablivi®, and Cablivi® is prescribed in combination with plasma exchange and immunosuppressive therapy (i.e., glucocorticoids, rituximab);
 - b. If request is for treatment extension, member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters: increase in platelet counts, reduction in neurological symptoms, or improvements in organ-damage markers (lactate dehydrogenase, cardiac troponin I, and serum creatinine);
3. Member has received no more than 58 days of Cablivi® therapy after completion of plasma exchange therapy;
4. Dose does not exceed the following:
 - a. For new treatment cycle: loading dose of 22 mg on day 1, followed by maintenance dose of 11 mg per day;
 - b. For treatment extension: 11 mg per day.

Approval Duration

Commercial: 58 days ost plasma-exchange

Medicaid: 58 days ost plasma-exchange

III. Appendices

APPENDIX A: Abbreviation/Acronym Key

aTTP: acquired thrombotic thrombocytopenic purpura

FDA: Food and Drug Administration

FFP: fresh frozen plasma
PEX: plasma exchange
vWF: von Willebrand factor

APPENDIX B: Therapeutic Alternatives

Below are suggested therapeutic alternatives based on clinical guidance. Please check drug formulary for preferred agents and utilization management requirements.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Plasma Exchange (PEX) <ul style="list-style-type: none"> • Fresh Frozen Plasma (FFP) • Solvent detergent/viral-inactivated plasma • Cryosupernatant 	1 to 1.5x estimated plasma volume daily until two days after normalization of platelet count ($\geq 150 \times 10^9/L$).	1 to 1.5x estimated plasma volume
methylprednisolone (Solu-Medrol®)	1mg/kg/day IV or PO during PEX and continued for 1 week after PEX. Tapered with the goal of being corticosteroid-free by Day 30 after PEX.	1 mg/kg/day
Rituxan® (rituximab)	375mg/m ² IV once weekly for 4 weeks or a reduced dose of 200 mg once weekly for 4 weeks administered immediately after PEX	375 mg/m ² once Weekly

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

APPENDIX C: Contraindications/Boxed Warnings

- Contraindication(s):
 - Previous severe hypersensitivity reaction to caplacizumab-yhdp or any of the excipients.
- Boxed Warning(s):
 - None.

APPENDIX D: General Information

- Discontinue Cablivi® if patient experiences more than 2 recurrences of aTTP while on Cablivi®.
- Recurrence is defined as a new decrease (while receiving Cablivi®) in the platelet count that necessitates reinitiation of plasma exchange after normalization of platelet count ($\geq 150,000/microL$) has occurred.
- Refractory disease is TTP that does not respond to initial treatment with PEX and glucocorticoids (e.g., lack of doubling of the platelet count within four days of initiation, occurrence of new neurologic symptoms not attributable to bleeding or infection).
- PLASMIC score for estimating the likelihood of severe ADAMTS13 deficiency in adults with suspected TTP (1 point for each)

- Platelet count < 30,000/microL
- One or more indicators of hemolysis: reticulocyte count > 2.5%, haptoglobin undetectable, or indirect bilirubin > 2.0 mg/dL [> 34mcmol/L]
- No active cancer in the preceding year
- No history of solid organ or hematopoietic stem cell transplant
- Mean corpuscular volume (MCV) < 90 femtoliters
- International normalized ratio (INR) < 1.5
- Creatinine < 2.0 mg/dL [< 177 mcmol/L]

PLASMIC score (points)	Risk of severe ADAMTS13 deficiency
0 to 4	Low Risk
5	Intermediate Risk
6 to 7	High Risk

References

1. Cablivi Prescribing Information. Ghent, Belgium: Ablynx N.V., Inc.; September 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761112s000lbl.pdf. Accessed January 30, 2021.
2. UpToDate [database online]. Waltham, MA; 2020. Available at: <https://uptodate.com>. Accessed January 30, 2021.
3. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019 Jan 24;380(4):335-346. Accessed January 30, 2021.
4. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British Journal of Haematology. 2012 Aug;158(3):323-35. Accessed January 30, 2021.
5. Page EE, Kremer-Hovinga JA, Terrell DR, et al. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016;127(24):3092. Accessed January 30, 2021.
6. Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematology. 2017;4(4):e157. Accessed January 30, 2021.

Review/Revision History	Review/Revision Date	P&T Approval Date
Policy established.	01/2020	02/07/2020
Policy was reviewed: <ol style="list-style-type: none"> 1) Clinical policy title was updated as “caplacizumab-yhdp”. 2) Line of business policies applies to All lines of business. 3) Continuation therapy criteria II.A.1. rephrased to “Member is currently receiving medication that has been authorized by RxAdvance or the member has met initial approval criteria listed in this policy”. 4) References were reviewed and 	01/30/2021	03/09/2021

updated.		
----------	--	--